The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumInsights - Shares of Pacira Pharmaceuticals (PCRX) took it on the chin at Thursday’s open as the company completely removed sales guidance for its only marketed product, Exparel. … Continue Reading
Read nowResearch - It’s happened– the first high-profile failure from the re-emerging cohort of publicly traded gene therapy developers. Celladon (CLDN) reported on Sunday that MYDICAR, the company’s … Continue Reading
Read nowRecap - Perhaps of most interest this week to long-time PropThink readers, Innate Pharma (IPH.PA)(IPHYF) took on AstraZeneca (AZN) as partner for the anti-NKG2A antibody IPH2201 on Friday morning, … Continue Reading
Read nowInsights - In a deal valued at $1.275 billion all-in, AstraZeneca (AZN) will partner with Innate Pharma (IPH.PA) for the development of IPH2201, Innate’s anti-NKG2A antibody. For … Continue Reading
Read nowInsights - An unexpected new contender in the race to develop a treatment for NASH (non-alcoholic steatohepatitis) emerged from a European medical conference on Thursday morning – the … Continue Reading
Read nowInsights - Teva (TEVA) made an official bid for rival drugmaker Mylan (MYL), which is in the middle of its own acquisition effort with a $29 billion bid for Perrigo (PRGO).
Read nowResearch - Completing their IPO in September 2014 and raising $56 million, Affimed Therapeutics (AFMD) is a German clinical-stage biopharmaceutical company developing targeted cancer immunotherapies. Affimed’s product … Continue Reading
Read now
